MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Editas Medicine Long Term Debt Current 2011-2026 | EDIT
Annual Long Term Debt Current Editas Medicine
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 14.7 M | 12.2 M | 11.1 M | 10.3 M | 6.81 M | 5.8 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 M | 5.8 M | 10.1 M |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
8.06 M | - | - | $ 866 M |  China |
 |
Apellis Pharmaceuticals
APLS
|
7.09 M | $ 20.22 | -2.32 % | $ 2.55 B |  USA |
 |
Aptorum Group Limited
APM
|
433 K | $ 0.82 | -3.48 % | $ 4.47 M | China |
 |
Axsome Therapeutics
AXSM
|
434 K | $ 164.71 | -1.01 % | $ 8.19 B | USA |
 |
AbCellera Biologics
ABCL
|
5.82 M | $ 3.73 | -2.49 % | $ 1.11 B |  Canada |
 |
Catalyst Pharmaceuticals
CPRX
|
437 K | $ 23.88 | - | $ 2.92 B | USA |
 |
Corvus Pharmaceuticals
CRVS
|
1.37 M | $ 18.08 | 1.06 % | $ 868 M | USA |
 |
Adverum Biotechnologies
ADVM
|
5.67 M | - | - | $ 86.2 M | USA |
 |
Certara
CERT
|
3.92 M | $ 7.19 | 1.93 % | $ 1.15 B | USA |
 |
Eton Pharmaceuticals
ETON
|
5.38 M | $ 17.72 | -2.37 % | $ 454 M | USA |
 |
Exelixis
EXEL
|
27.9 M | $ 40.99 | -0.1 % | $ 11.1 B | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Galapagos NV
GLPG
|
3.48 M | $ 33.13 | -2.82 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
26 M | $ 27.67 | -6.69 % | $ 17.7 B |  Danmark |
 |
Capricor Therapeutics
CAPR
|
749 K | $ 26.04 | -3.07 % | $ 697 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
2.83 M | $ 0.99 | -2.92 % | $ 72.7 M | USA |
 |
Halozyme Therapeutics
HALO
|
13.3 M | $ 69.39 | -0.67 % | $ 8.32 B | USA |
 |
Harmony Biosciences Holdings
HRMY
|
1.07 M | $ 28.56 | -1.19 % | $ 1.64 B | USA |
 |
ImmuCell Corporation
ICCC
|
432 K | $ 6.3 | -3.67 % | $ 51.5 M | USA |
 |
CureVac N.V.
CVAC
|
3.47 M | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
271 K | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
428 K | - | -10.17 % | $ 12.2 K | USA |
 |
Immuron Limited
IMRN
|
34.4 K | $ 0.75 | -0.69 % | $ 6.43 M |  Australia |
 |
Immatics N.V.
IMTX
|
1.88 M | $ 9.86 | -1.3 % | $ 620 M | Germany |
 |
Immunic
IMUX
|
470 K | $ 1.1 | 3.3 % | $ 171 M | USA |
 |
Immunovant
IMVT
|
98 K | $ 26.99 | -2.74 % | $ 4.09 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Inhibrx
INBX
|
2.06 M | $ 75.96 | -1.97 % | $ 3.58 B | USA |
 |
InMed Pharmaceuticals
INM
|
376 K | $ 0.75 | -8.49 % | $ 1.84 M | Canada |
 |
INmune Bio
INMB
|
119 K | $ 1.41 | 6.07 % | $ 25.4 M | USA |
 |
Insmed Incorporated
INSM
|
9.47 M | $ 146.89 | 0.39 % | $ 29.2 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
1.27 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
410 K | - | 1.93 % | $ 17.4 M | USA |
 |
Agenus
AGEN
|
2.59 M | $ 3.19 | -4.49 % | $ 1.14 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M |  Israel |
 |
Agios Pharmaceuticals
AGIO
|
18.4 M | $ 29.11 | -0.31 % | $ 1.69 B | USA |